News Release Details
Halozyme Therapeutics Announces Executive Transitions
Helen Torley to assume role of President and CEO; Gregory I. Frost to lead Intrexon's Health Sector and will remain on Halozyme's Scientific Advisory Board
SAN DIEGO, Dec. 17, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that Helen Torley, M.B. Ch. B., M.R.C.P., will be joining Halozyme as President and Chief Executive Officer on January 6, 2014. She will also become a member of Halozyme's Board of Directors. Dr. Torley was most recently Executive Vice President and Chief Commercial Officer at Onyx Pharmaceuticals, a subsidiary of Amgen. Gregory I. Frost, Ph.D. is departing Halozyme for Intrexon (NYSE: XON), assuming the head of that company's Health Sector, and will continue to lead Halozyme's Scientific Advisory Board. Dr. Frost will join Intrexon effective January 6, 2014.
Rays, this is the stock I was telling you about a while back. I had bought it at $9.85 and sold it $13. This is where I went when I left CLDX a couple of months ago. I bought it thinking it would hit $20 before CLDX hit $40. I think that thinking may be more accurate now, but nevertheless, I am in CLDX now and not in HALO.